These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22214534)

  • 1. Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors.
    Rousseau C; Ruellan AL; Bernardeau K; Kraeber-Bodéré F; Gouard S; Loussouarn D; Saï-Maurel C; Faivre-Chauvet A; Wijdenes J; Barbet J; Gaschet J; Chérel M; Davodeau F
    EJNMMI Res; 2011 Sep; 1(1):20. PubMed ID: 22214534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panitumumab-DOTA-
    Facca VJ; Cai Z; Gopal NEK; Reilly RM
    Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
    Verel I; Visser GW; Vosjan MJ; Finn R; Boellaard R; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1645-52. PubMed ID: 15290121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.
    Rousseau C; Ferrer L; Supiot S; Bardiès M; Davodeau F; Faivre-Chauvet A; Baumgartner P; Wijdenes J; Lacombe M; Barbet J; Guillaume T; Moreau P; Harousseau JL; Kraeber-Bodéré F; Cherel M
    Tumour Biol; 2012 Jun; 33(3):679-88. PubMed ID: 22389160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Kasten BB; Oliver PG; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29561763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
    Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
    J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis.
    Park BN; Kim GH; Ko SA; Shin GH; Lee SJ; An YS; Yoon JK
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
    Tassone P; Goldmacher VS; Neri P; Gozzini A; Shammas MA; Whiteman KR; Hylander-Gans LL; Carrasco DR; Hideshima T; Shringarpure R; Shi J; Allam CK; Wijdenes J; Venuta S; Munshi NC; Anderson KC
    Blood; 2004 Dec; 104(12):3688-96. PubMed ID: 15292058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model.
    Fichou N; Gouard S; Maurel C; Barbet J; Ferrer L; Morgenstern A; Bruchertseifer F; Faivre-Chauvet A; Bigot-Corbel E; Davodeau F; Gaschet J; Chérel M
    Front Med (Lausanne); 2015; 2():76. PubMed ID: 26582128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy for CD133(+) colonic cancer stem cells inhibits tumor development in nude mice.
    Weng D; Jin X; Qin S; Lan X; Chen C; Sun X; She X; Dong C; An R
    Oncotarget; 2017 Jul; 8(27):44004-44014. PubMed ID: 28430648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Auger Electron-Emitting Radioimmunotherapy with [
    Facca VJ; Cai Z; Ku A; Georgiou CJ; Reilly RM
    Mol Pharm; 2023 Dec; 20(12):6407-6419. PubMed ID: 37983089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.
    Govindan SV; Stein R; Qu Z; Chen S; Andrews P; Ma H; Hansen HJ; Griffiths GL; Horak ID; Goldenberg DM
    Breast Cancer Res Treat; 2004 Mar; 84(2):173-82. PubMed ID: 14999147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
    J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model.
    Kim KI; Jang SJ; Park JH; Lee YJ; Lee TS; Woo KS; Park H; Choe JG; An GI; Kang JH
    J Nucl Med; 2014 Oct; 55(10):1692-8. PubMed ID: 25091475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (64)Cu-labeled peptide for PET of breast carcinomas expressing the Thomsen-Friedenreich carbohydrate antigen.
    Kumar SR; Gallazzi FA; Quinn TP; Deutscher SL
    J Nucl Med; 2011 Nov; 52(11):1819-26. PubMed ID: 21984800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.